–TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and shorter duration of ...

Post this The “extra-strength” glabellar line study is a multicenter, double-blind, randomized, Phase 2 trial following 150 patients for up to 12 months or until the patient loses their correction.

There’s a new age-defying treatment coming to a dermatology office near you. Rivaling widely popular anti-aging injectables like Botox and Daxxify, the recently FDA-approved neuromodulator Letybo has ...

BOTOX® Cosmetic is the first neurotoxin approved in China for the treatment of masseter muscle prominence (MMP), the largest global market for MMP. Approval supported by well-established safety ...

The potency units of Letybo are not interchangeable with other preparations of botulinum toxin products. The Food and Drug Administration (FDA) has approved Letybo (letibotulinumtoxinA-wlbg) for the ...

Revance Therapeutics' share price has been characterised by volatility ever since its IPO - but today shares trade close to an all-time low. The company's focus is on maximising the potential of ...

Please provide your email address to receive an email when new articles are posted on . Xeomin is the first neurotoxin that can simultaneously treat frown lines, forehead lines and crow’s feet. Xeomin ...

South Korea's market leading neurotoxin in aesthetics set to launch in the second half of 2024. NEWPORT BEACH, Calif., March 4, 2024 /PRNewswire/ -- Hugel America, Inc., a division of Hugel Inc., a ...

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 1 study titled A Phase 1 Study With AGN ...

Can you ever be too old (or young) for Botox? Apparently not. It’s being embraced by all ages – from teens to women in their 80s – and is becoming the century’s hotshot anti-ageing treatment.